Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 145

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 145
---
5 between NewGenIvf and GIVF (“Purchase Agreement”), NewGenIvf purchased all
of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort
technology from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Ordinary Shares (equivalent to 12,500
Ordinary Shares post Second Reverse Stock Split) (“MicroSort Acquisition”).

Prior to the closing of
the MicroSort Acquisition, NewGenIvf held an exclusive license granted by a division of GIVF, MicroSort International, to use the MicroSort
technology in Thailand and Cambodia. MicroSort’s licenses for NewGenIvf’s operation in Thailand and Cambodia were each provided
under a lease and service agreement. In April 2019, First Fertility PGS entered into a Lease and Services Agreement with MicroSort International
to use MicroSort equipment in Thailand and in March 2019, Phnom Penh Center entered into a Lease and Services Agreement with MicroSort
International to use MicroSort equipment in Cambodia (together, the “Lease and Services Agreements”). Pursuant to the Lease
and Services Agreements, First Fertility PGS and Phnom Penh Center each had the exclusive right to utilize the MicroSort equipment and
to market and sell MicroSort sperm sorting services in Thailand and Cambodia, respectively. MicroSort International was responsible for
the maintenance of MicroSort equipment and technical and engineering support. The term of each Lease and Service Agreements was initially
from 2019 to 2024, which shall be automatically renewed for one year unless a written notice of at least 180 days prior to the intended
termination date is provided. The consideration under each of the Lease and Services Agreements was US$9,000 per month after six months
from the effective date of the agreements.

The flow chart below shows
the process involved in MicroSort:

Preimplantation Genetic Screening

PGS is used in parallel with
an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too few chromosomes) in a developing
embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid embryos that have a higher chance of
implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf by achieving a higher implantation rate